世界の高コレステロール血症治療市場 – 2031 年までの業界動向と予測

高コレステロール血症治療市場の分析と規模

心血管疾患の予防は、高コレステロール血症治療市場の主な用途です。薬物療法とライフスタイルの変更により高コレステロール値を管理および低下させることで、心臓発作、脳卒中、その他の心血管疾患のリスクが大幅に軽減されます。この予防的アプローチは、個人の健康状態を改善するだけでなく、心血管イベントの発生率を低下させることで医療システムへの全体的な負担を軽減します。効果的な高コレステロール血症管理による予防に重点を置くことで、公衆衛生の向上における市場の重要な役割が強調されます。

世界の高コレステロール血症治療市場規模は、2023年に174億9,000万米ドルと評価され、2024年から2031年の予測期間中に16.2%のCAGRで成長し、2031年には581億3,000万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

レポートの範囲と市場セグメンテーション       

Market Definition

Hypercholesterolemia treatment involves managing high levels of cholesterol in the blood to reduce the risk of cardiovascular diseases. It typically includes lifestyle changes such as a healthy diet and regular exercise, along with medications such as statins, fibrates, or PCSK9 inhibitors to lower cholesterol levels. The goal is to achieve and maintain a healthy cholesterol balance to prevent heart attacks and strokes.

Hypercholesterolemia Treatment Market Dynamics

Drivers                                                                                          

• Rising Prevalence of Hypercholesterolemia

With rising levels of unhealthy lifestyles, poor diets, and sedentary behavior, the prevalence of high cholesterol is escalating globally. This surge necessitates effective treatment options to manage and lower cholesterol levels, fueling demand for medications such as statins, fibrates, and PCSK9 inhibitors. Additionally, the growing awareness of the risks associated with high cholesterol, including cardiovascular diseases, prompts more individuals to seek medical intervention, further propelling the treatment market's growth.

According to the World Health Organization (WHO), hypercholesterolemia leads to over 2.6 million deaths annually. With 37.0% of U.S. adults having elevated LDL-C levels and less than 50.0% of treated patients achieving normal lipid levels, the demand for effective hypercholesterolemia treatments is significantly boosted.

• Growing Awareness about Health Risks

As more individuals become informed about the link between elevated cholesterol and cardiovascular diseases such as heart attacks and strokes, there is an increased demand for effective treatment options. This awareness prompts people to seek medical advice and screening for cholesterol levels earlier, leading to earlier diagnosis and intervention. Healthcare providers are also increasingly proactive in educating patients about lifestyle modifications and medication adherence, further driving the market for cholesterol-lowering therapies. Additionally, public health campaigns and initiatives focused on preventive care contribute to raising awareness and reducing the burden of hypercholesterolemia-related complications.

Opportunities

• Growing Technological Advancements

Technological advancements include innovations in drug delivery systems, such as sustained-release formulations and nanotechnology-based therapies, which improve the efficacy and patient compliance of cholesterol-lowering medications. Moreover, advancements in diagnostic technologies such as genetic testing and biomarker identification enable more precise diagnosis and personalized treatment plans for patients with hypercholesterolemia. Furthermore, ongoing research into novel therapeutic targets, such as PCSK9 inhibitors and RNA-based therapies, promises to expand treatment options and enhance outcomes for individuals with high cholesterol levels.

• Rising Supportive Government Policies

Governments worldwide are increasingly recognizing the public health burden posed by cardiovascular diseases linked to high cholesterol levels. As a result, they are implementing policies aimed at promoting preventive healthcare measures, improving access to lipid-lowering medications, and enhancing screening and diagnosis programs for hypercholesterolemia. Financial incentives, subsidies for healthcare services, and regulatory frameworks that expedite drug approvals also stimulate pharmaceutical innovation in this sector. These policies create a conducive environment for pharmaceutical companies to invest in research and development, leading to the development of more effective and accessible treatments for hypercholesterolemia.

Restraints/Challenges

• High Cost of Medications

Drugs such as PCSK9 inhibitors, which are newer and highly effective at lowering cholesterol, come with a hefty price tag. This high cost can limit access for patients, particularly those without adequate insurance coverage or financial resources. Healthcare systems and insurers often face challenges in covering these expenses, leading to delays or denials in access to necessary treatments. Moreover, the affordability issue may impact patient compliance and adherence to prescribed therapies, ultimately affecting treatment outcomes.

• Availability of Alternative Therapies

Some individuals opt for alternative approaches such as dietary supplements, herbal remedies, or lifestyle modifications instead of conventional medications such as statins. While these alternatives may appeal to patients seeking natural or holistic treatments, they often lack rigorous scientific evidence supporting their effectiveness and safety in managing cholesterol levels. This trend can divert patients from medically proven treatments, potentially delaying or preventing them from achieving optimal lipid control and increasing their risk of cardiovascular complications

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Hypercholesterolemia Treatment Market Scope

The market is segmented on the basis of treatment, drug type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Diagnosis
• Medication
• Physical Therapy
• Others

Drug Type

• AEM-2802
• AEM-2814
• Alirocumab
• Evinacumab
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hypercholesterolemia Treatment Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by, treatment, drug type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the market report are the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.

North America is expected to dominate the market due to the high prevalence of hypercholesterolemia. Approximately 28.5 million adults in the U.S., representing nearly 12% of the adult population, have total cholesterol levels of 240 mg/dL or higher. This significant incidence of elevated cholesterol levels drives the demand for treatments and interventions, positioning North America as a key market. The region's advanced healthcare infrastructure and awareness programs further contribute to its market dominance.

アジア太平洋地域は、技術の大幅な進歩と医療費の増加により、市場の成長が見込まれています。中国、日本、インドなどの国々は、最先端の医療技術とインフラに多額の投資を行っており、市場の成長を牽引しています。さらに、可処分所得の増加と医療サービスの向上を目指す政府の取り組みも、この地域の優位性に貢献しています。これらの国々で拡大している中流階級は、より良い医療を求めており、市場拡大をさらに後押ししています。これらの要因の組み合わせにより、アジア太平洋地域は世界市場の主要プレーヤーとしての地位を確立しています。

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、各国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。

ヘルスケアインフラの成長 導入基盤と新技術の浸透

この市場では、各国の医療設備支出の増加、市場向け各種製品のインストールベース、ライフライン曲線を使用した技術の影響、医療規制シナリオの変化と市場への影響など、詳細な市場分析も提供しています。データは、2016年から2021年までの履歴期間について利用可能です。

競争環境と高コレステロール血症治療市場の分析

市場競争環境では、競合他社ごとの詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などが含まれます。提供される上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。

市場で活動している主要企業は次のとおりです。

• ファイザー社（米国）
• ノバルティスAG（スイス）
• アムジェン社（米国）
• ベーリンガーインゲルハイムインターナショナルGmbH（ドイツ）
• メルク社（米国）
• サン・ファーマシューティカル・インダストリーズ（インド）
• テバ・ファーマシューティカルズ・インダストリーズ社（イスラエル）
• アストラゼネカ（英国）
• フレゼニウス カビ AG (ドイツ)
• バイエルAG（ドイツ）
• オーロビンドファーマ（インド）
• アッヴィ社（米国）
• メリンタ・セラピューティクス社（米国）

SKU-56988